Phosphaturic Mesenchymal Tumor
From Invisibility to Bedridden Morbidity
DOI:
https://doi.org/10.15605/jafes.041.02.5185Keywords:
Oncogenic osteomalacia, phosphaturic mesenchymal tumor, FGF 23, hypophosphatemia, paraneoplastic syndromeAbstract
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by fibroblast growth factor 23 (FGF23) secreting phosphaturic mesenchymal tumors. We report a 53-year-old man with progressive osteomalacia resulting in bedridden status. Renal phosphate wasting despite normal vitamin D, intact parathormone, and renal function raised suspicion of TIO, confirmed by elevated FGF23. However, the occult tumor was localized only by Ga-68 DOTANOC wholebody PET-CT, highlighting the diagnostic challenges in TIO.
Downloads
References
1. Minisola S, Fukumoto S, Xia W, et al. Tumor-induced osteomalacia: A comprehensive review. Endocr Rev. 2023;44(2):323-53. https://pubmed.ncbi.nlm.nih.gov/36327295 https://doi.org/10.1210/endrev/bnac026
2. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. https://pubmed.ncbi.nlm.nih.gov/14707860 https://doi.org/10.1097/00000478-200401000-00001
3. Folpe AL. Phosphaturic mesenchymal tumors: A review and update. Semin Diagn Pathol. 2019;36(4):260-8. https://pubmed.ncbi.nlm.nih.gov/31301876 https://doi.org/10.1053/j.semdp.2019.07.002
4. Evans DJ, Azzopardi JG. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet. 1972;1(7746):353-4. https://pubmed.ncbi.nlm.nih.gov/4109739 https://doi.org/10.1016/s0140-6736(72)92844-9
5. Abrahamsen B, Smith CD, Minisola S. Epidemiology of tumor-induced osteomalacia in Denmark. Calcif Tissue Int. 2021;109(2):147-56. https://pubmed.ncbi.nlm.nih.gov/33818653 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273058 https://doi.org/10.1007/s00223-021-00843-2
6. Yin Z, Du J, Yu F, Xia W. Tumor-induced osteomalacia. Osteoporos Sarcopenia. 2018;4(4):119-27. https://pubmed.ncbi.nlm.nih.gov/30775554 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372818 https://doi.org/10.1016/j.afos.2018.12.001
7. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770-4. https://pubmed.ncbi.nlm.nih.gov/17086194 https://doi.org/10.1038/nature05315
8. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-35. https://pubmed.ncbi.nlm.nih.gov/15040831 https://doi.org/10.1359/JBMR.0301264
9. Ackah SA, Imel EA. Approach to hypophosphatemic rickets. J Clin Endocrinol Metab. 2022;108(1):209-20. https://pubmed.ncbi.nlm.nih.gov/35981346 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759174 https://doi.org/10.1210/clinem/dgac488
10. Hacisahinogullari H, Tekin S, Tanrikulu S, et al. Diagnosis and management of tumor-induced osteomalacia: A single center experience. Endocrine. 2023;82(2):427-34. https://pubmed.ncbi.nlm.nih.gov/37480497 https://doi.org/10.1007/s12020-023-03450-3
11. Lee JC, Jeng YM, Su SY, et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol. 2015;235(4):539-45. https://pubmed.ncbi.nlm.nih.gov/25319834 https://doi.org/10.1002/path.4465. Erratum in J Pathol. 2015;236(1):131.
12. Lee JC, Su SY, Changou CA, et al. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol. 2016;29(11):1335-46. https://pubmed.ncbi.nlm.nih.gov/27443518 PMCID: PMC13417894 https://doi.org/10.1038/modpathol.2016.137
13. World Health Organization Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. International Agency for Research on Cancer; 2020
14. Benson JC, Trejo-Lopez JA, Nassiri AM, et al. Phosphaturic mesenchymal tumor. AJNR Am J Neuroradiol. 2022;43(6):817-22. https://pubmed.ncbi.nlm.nih.gov/35589138 PMCID: PMC9172954 https://doi.org/10.3174/ajnr.A7513
15. Agaimy A, Michal M, Chiosea S, et al. Phosphaturic mesenchymal tumors: Clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol. 2017;41(10):1371-80. https://pubmed.ncbi.nlm.nih.gov/28614212 https://doi.org/10.1097/PAS.0000000000000890
16. Álvarez-Rivas N, Lugo-Rodríguez G, Maneiro JR, et al. Tumor-induced osteomalacia: A systematic literature review. Bone Rep. 2024;21:101772. https://pubmed.ncbi.nlm.nih.gov/38774264 PMCID: PMC11107251 https://doi.org/10.1016/j.bonr.2024.101772
17. Rendina D, Abate V, Cacace G, et al. Tumor-induced osteomalacia: A systematic review and individual patient's data analysis. J Clin Endocrinol Metab. 2022;107(8):e3428-36. https://pubmed.ncbi.nlm.nih.gov/35468192 https://doi.org/10.1210/clinem/dgac253
18. Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017;3:17044. https://pubmed.ncbi.nlm.nih.gov/28703220 https://doi.org/10.1038/nrdp.2017.44
19. Jan de Beur SM, Miller PD, Weber TJ, et al. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2021;36(4):627-35. https://pubmed.ncbi.nlm.nih.gov/33338281 PMCID: PMC8247961 https://doi.org/10.1002/jbmr.4233
20. Jiang Y, Li X, Huo L, et al; Chinese Society of Osteoporosis and Bone Mineral Research and Chinese Society of Endocrinology. Consensus on clinical management of tumor-induced osteomalacia. Chin Med J (Engl). 2021;134(11):1264-6. https://pubmed.ncbi.nlm.nih.gov/33813513 PMCID: PMC8183716 https://doi.org/10.1097/CM9.0000000000001448
21. Shi X, Jing H, Li F, Zhao Y, Wang Z, Huo L. 99mTc-HYNIC-TOC in the evaluation of recurrent tumor-induced osteomalacia. Clin Nucl Med. 2019;44(3):209-13. https://pubmed.ncbi.nlm.nih.gov/30672760 https://doi.org/10.1097/RLU.0000000000002458
22. Dahir K, Zanchetta MB, Stanciu I, et al. Diagnosis and management of tumor-induced osteomalacia: Perspectives from clinical experience. J Endocr Soc. 2021;5(9):bvab099. https://pubmed.ncbi.nlm.nih.gov/34286168 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282217 https://doi.org/10.1210/jendso/bvab099
23. Ito N, Shimizu Y, Suzuki H, et al. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010;268(4):390-4. https://pubmed.ncbi.nlm.nih.gov/20698924 https://doi.org/10.1111/j.1365-2796.2010.02262.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ramita Mukherjee, Santosha Kumar Pattashanee, Brijesh Kumar Singh, Asuri Krishna, Sushant Soren, A Nishikant Damle, M C Sharma, V Seenu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
